FDA HIV Treatment and Prevention Agents Packaging 
Pharmacy Friday Pearls
MARCH 4, 2022
18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.
ISPE
JULY 6, 2023
1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Table 1: List of FDA-approved commercial products using CM elements. Table 1: List of FDA-approved commercial products using CM elements. This is demonstrated by the rise from $1.05
Expert insights. Personalized for you.
40 
Let's personalize your content